Blind liver biopsy: a 17-year experience

Autores/as

  • Nafiye Urganci SBU Sisli Etfal Training and Research Hospital
  • Tugce Kurtaraner SBU Sisli Etfal Training and Research Hospital
  • Derya Kalyoncu Istinye State Hospital, Pediatrics.
  • Ayse Merve Usta SBU Sisli Etfal Training and Research Hospital
  • Banu Yilmaz Ozguven SBU Sisli Etfal Training and Research Hospital

DOI:

https://doi.org/10.47892/rgp.2020.404.1206

Palabras clave:

Biopsy, Liver, Pediatric, complications

Resumen

Objectives: Liver biopsy is the gold standard for assessing liver inflammation, necrosis and fibrosis. The aim of the study is to evaluate clinical indications and histopathological results of percutaneus liver biopsy. Materials and methods: A total of 516 children who underwent blind liver biopsy were evaluated retrospectively. Results: Blind liver biopsy was performed for chronic active hepatitis B in 50% of the cases (n=260), neonatal cholestasis in 14% (n=68), autoimmune hepatitis in 7.7% (n=40), Wilson disease in 7.3% (n=38), isolated elevation of the liver enzymes in 5% (n=26), chronic active hepatitis C in 4.2% (n=22), metabolic disease in 3.4% (n=17), malignancies in 2.2% (n=11) and the others in 3.4% (n=17). Major complications were observed in 0.19% of the cases (n=1) and minor complications such as pain at the biopsy site in 13.5% of the cases (n=70), hypotension and tachycardia in 1.9% (n=10). Conclusions: Blind liver biopsy is a safe method in diagnosing liver diseases in childhood.

Descargas

Métricas

Visualizaciones del PDF
271
Jan 2021Jul 2021Jan 2022Jul 2022Jan 2023Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 202654
|

Descargas

Publicado

31.12.2020

Cómo citar

1.
Urganci N, Kurtaraner T, Kalyoncu D, Merve Usta A, Yilmaz Ozguven B. Blind liver biopsy: a 17-year experience. Rev Gastroenterol Peru [nternet]. 31 de diciembre de 2020 [citado 14 de abril de 2025];40(4):322-8. isponible en: https://revistagastroperu.com/index.php/rgp/article/view/1206

Número

Sección

ARTÍCULOS ORIGINALES